Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ESP025
MIFTS: 40

Esophagus Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Esophagus Adenocarcinoma

About this section

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 12 15
Adenocarcinoma of Esophagus 43 71
Oesophageal Adenocarcinoma 12

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Gastrointestinal diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:4914
MeSH 43 C562730
NCIt 49 C4025
UMLS 71 C0279628
Sources

Summaries for Esophagus Adenocarcinoma

About this section
Disease Ontology : 12 An esophageal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Esophagus Adenocarcinoma, also known as adenocarcinoma of esophagus, is related to signet ring cell adenocarcinoma and atrophic gastritis. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Cisplatin and Cetuximab have been mentioned in the context of this disorder. Affiliated tissues include breast, lung and skin, and related phenotypes are digestive/alimentary and neoplasm

Sources

Related Diseases for Esophagus Adenocarcinoma

About this section

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 345)
# Related Disease Score Top Affiliating Genes
1 signet ring cell adenocarcinoma 30.5 TP53 ERBB2 CDX2
2 atrophic gastritis 30.4 TP53 PTGS2 CDX2
3 gastritis 30.4 TP53 PTGS2 CDX2 ATP4A
4 adenocarcinoma 30.4 TP53 PTGS2 HNF1A-AS1 ERBB2 EGFR CDX2
5 active peptic ulcer disease 30.3 PTGS2 ATP4A ATP12A
6 peptic ulcer disease 30.3 TP53 PTGS2 ATP4A ATP12A
7 bile reflux 30.3 PTGS2 CDX2 ATP4A ATP12A
8 barrett esophagus 30.3 TP53 PTGS2 ERBB2 EGFR CDX2 CDKN2A
9 adenocarcinoma in situ 30.2 MIR21 EGFR CDX2 CDKN2A
10 rectum cancer 30.1 MIR21 MIR196A1 MIR193A MIR145 MIR143
11 esophagitis 30.1 TP53 PTGS2 EGFR CDKN2A
12 tubular adenocarcinoma 30.0 MIR21 ERBB2 EGFR CDX2
13 exanthem 30.0 ERBB2 EGFR ATP4A ATP12A
14 barrett's adenocarcinoma 30.0 TP53 TAGLN2 PTGS2 ERBB2 COX7A2 CDKN2A
15 tongue cancer 29.9 TP53 MIR21 EGFR CDKN2A
16 adenoma 29.9 TP53 PTGS2 CDX2 CDKN2A
17 gastric adenocarcinoma 29.9 TP53 PTGS2 ERBB2 EGFR CDX2 CDKN2A
18 small cell carcinoma 29.9 TP53 EGFR CDX2 CDKN2A
19 papilloma 29.8 TP53 PTGS2 EGFR CDKN2A
20 colon adenocarcinoma 29.7 TP53 PTGS2 MIR21 ERBB2 EGFR
21 in situ carcinoma 29.5 TP53 MIR193A MIR143 ERBB2 EGFR CDKN2A
22 squamous cell carcinoma 29.5 TP53 PTGS2 HNF1A-AS1 ERBB2 EGFR CDKN2A
23 esophageal cancer 28.5 TP53 PTGS2 MIR330 MIR21 MIR196A1 MIR193A
24 gastric cancer 28.5 TP53 PTGS2 MIR215 MIR21 MIR196A1 MIR145
25 colorectal cancer 27.7 TP53 PTGS2 MIR215 MIR21 MIR196A1 MIR193A
26 pancreatic vasoactive intestinal peptide producing tumor 10.6 ATP4A ATP12A
27 hemangioma of intra-abdominal structure 10.6 ATP4A ATP12A
28 displacement of cardia through esophageal hiatus 10.6 ATP4A ATP12A
29 gastric hemangioma 10.6 ATP4A ATP12A
30 acquired gastric outlet stenosis 10.6 ATP4A ATP12A
31 angiodysplasia of intestine 10.6 ATP4A ATP12A
32 benzylpenicillin allergy 10.6 ATP4A ATP12A
33 median arcuate ligament syndrome 10.6 ATP4A ATP12A
34 granulomatous gastritis 10.6 ATP4A ATP12A
35 bacterial esophagitis 10.6 ATP4A ATP12A
36 lingual goiter 10.6 ATP4A ATP12A
37 cascade stomach 10.6 ATP4A ATP12A
38 gastrojejunal ulcer 10.6 ATP4A ATP12A
39 fungal esophagitis 10.6 ATP4A ATP12A
40 gastric gastrinoma 10.6 ATP4A ATP12A
41 fungal gastritis 10.6 ATP4A ATP12A
42 superior mesenteric artery syndrome 10.6 ATP4A ATP12A
43 cervix erosion 10.6 ATP4A ATP12A
44 pneumatosis cystoides intestinalis 10.5 ATP4A ATP12A
45 dieulafoy lesion 10.5 ATP4A ATP12A
46 esophagus sarcoma 10.5 ATP4A ATP12A
47 esophagus melanoma 10.5 ATP4A ATP12A
48 polyposis, skin pigmentation, alopecia, and fingernail changes 10.5 ATP4A ATP12A
49 gastric papillary adenocarcinoma 10.5 TP53 ERBB2
50 necrotizing gastritis 10.5 ATP4A ATP12A

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma
Sources

Symptoms & Phenotypes for Esophagus Adenocarcinoma

About this section

MGI Mouse Phenotypes related to Esophagus Adenocarcinoma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.56 ATP12A ATP4A CDKN2A CDX2 EGFR ERBB2
2 neoplasm MP:0002006 9.17 ATP4A CDKN2A CDX2 EGFR ERBB2 PTGS2
Sources

Drugs & Therapeutics for Esophagus Adenocarcinoma

About this section

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 114)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
2
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
3
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
4
Dexlansoprazole Approved, Investigational Phase 2, Phase 3 138530-94-6, 103577-45-3 9578005
5
Theophylline Approved Phase 2, Phase 3 58-55-9 2153
6
Lansoprazole Approved, Investigational Phase 2, Phase 3 103577-45-3 3883
7
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
8
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
9 Antineoplastic Agents, Immunological Phase 3
10 Antimitotic Agents Phase 3
11 Gastrointestinal Agents Phase 2, Phase 3
12 Neurotransmitter Agents Phase 2, Phase 3
13 Anti-Asthmatic Agents Phase 2, Phase 3
14 Proton Pump Inhibitors Phase 2, Phase 3
15 Respiratory System Agents Phase 2, Phase 3
16 Anti-Ulcer Agents Phase 2, Phase 3
17 Vasodilator Agents Phase 2, Phase 3
18 Autonomic Agents Phase 2, Phase 3
19 Bronchodilator Agents Phase 2, Phase 3
20 Phosphodiesterase Inhibitors Phase 2, Phase 3
21 Antacids Phase 2, Phase 3
22 Pharmaceutical Solutions Phase 3
23 Albumin-Bound Paclitaxel Phase 3
24
Epirubicin Approved Phase 2 56420-45-2 41867
25
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
26
Trioxsalen Approved Phase 2 3902-71-4 5585
27
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 5310940 9887054 6857599 43805
28
Panitumumab Approved, Investigational Phase 2 339177-26-3 50070211
29
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
30
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030 46835353
31
Everolimus Approved Phase 2 159351-69-6 6442177 70789204
32
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
33
Lenograstim Approved, Investigational Phase 2 135968-09-1
34
Melphalan Approved Phase 2 148-82-3 4053 460612
35
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
36
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
37
Pertuzumab Approved Phase 2 380610-27-5, 145040-37-5 2540
38
Durvalumab Approved, Investigational Phase 1, Phase 2 1428935-60-7
39
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
40
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
41
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
42
Fluorouracil Approved Phase 2 51-21-8 3385
43
leucovorin Approved Phase 2 58-05-9 6006 143
44
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
45
Pancrelipase Approved, Investigational Phase 2 53608-75-6
46
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
47
Hydroxyurea Approved Phase 2 127-07-1 3657
48
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
49
Calcium Approved, Nutraceutical Phase 2 7440-70-2 271
50
Alvocidib Experimental, Investigational Phase 2 146426-40-6, 131740-09-5 5287969

Interventional clinical trials:

(show top 50) (show all 76)
# Name Status NCT ID Phase Drugs
1 A PROSPECTIVE RANDOMISED NON SURGICAL TREATMENT OF OESOPHAGEAL CANCER WITH COMBINED CHEMOTHERAPY AND EXTERNAL BEAM IRRADIATION WITH VS WITHOUT HIGH-DOSE BRACHYTHERAPY Unknown status NCT00002884 Phase 3 chemotherapy;cisplatin;fluorouracil
2 A PHASE III INTERGROUP RANDOMIZED COMPARISON OF COMBINED MODALITY THERAPY FOR CARCINOMA OF THE ESOPHAGUS: HIGH-DOSE VS CONVENTIONAL-DOSE RADIATION THERAPY Completed NCT00002631 Phase 3 chemotherapy;cisplatin;fluorouracil
3 The Evaluation of Effectiveness Between Empirical and Guided Therapy for Unexplained Non-Cardiac Chest Pain Completed NCT03319121 Phase 2, Phase 3 Empirical therapy group;Guided therapy group
4 A Prospective Randomized Phase III Trial Comparing Trimodality Therapy (Cisplatin, 5-FU, Radiotherapy, and Surgery) to Surgery Alone for Esophageal Cancer Completed NCT00003118 Phase 3 cisplatin;fluorouracil
5 Randomised Phase III Study of Docetaxel vs Active Symptom Control in Patients With Relapsed Oesophago-gastric Adenocarcinoma Completed NCT00978549 Phase 3 docetaxel;steroid therapy
6 Multimodal Therapy With and Without Cetuximab in Patients With Locally Advanced Esophageal Carcinoma - An Open-Label Phase III Trial Completed NCT01107639 Phase 3 cisplatin;docetaxel
7 Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus Recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
8 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Patients With Advanced Esophageal Cancer Unknown status NCT00003326 Phase 2 paclitaxel
9 The Effect of Preoperative Docetaxel, Cisplatin and Capecitabine on Serum RUNX3 Hypermethylation Status in Patients With Gastric and Lower Oesophagus Adenocarcinoma. Unknown status NCT00674167 Phase 2 Docetaxel;Cisplatin;Capecitabine
10 Esophageal Cancer: A Phase II Study of Paclitaxel, Carboplatin and 5-Fluorouracil With Simultaneous Radiotherapy Followed by Surgical Resection Unknown status NCT00006472 Phase 2 carboplatin;fluorouracil;paclitaxel
11 Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
12 Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan
13 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
14 A Phase II Study of Neoadjuvant Therapy With Cisplatin, Docetaxel, Panitumumab Plus Radiation Therapy Followed by Surgery in Patients With Locally Advanced Adenocarcinoma of the Distal Esophagus Completed NCT00757172 Phase 2 cisplatin;docetaxel
15 Phase II Single-Arm Trial Of CPT-11 (Irinotecan HC1; Camptosar Injection)/Cisplatin In Patients With Advanced Esophageal Cancer Completed NCT00030862 Phase 2 cisplatin;irinotecan hydrochloride
16 Gemcitabine Plus Irinotecan in Patients With Esophageal Cancer, Phase II Completed NCT00012363 Phase 2 gemcitabine hydrochloride;irinotecan hydrochloride
17 Phase II Trial of Flavopiridol and Paclitaxel in Patients With Paclitaxel-Refractory Esophageal Cancer Completed NCT00006245 Phase 2 alvocidib;paclitaxel
18 A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus Completed NCT00165191 Phase 2 Doxorubicin;Cisplatin;5-fluorouracil
19 A Phase II Multicenter Study of the Efficacy and Safety Study of PNU-93914 (Liposome Encapsulated Paclitaxel) in Patients With Advanced Esophageal Cancer Previously Exposed to Chemotherapy Completed NCT00016900 Phase 2 liposomal paclitaxel
20 Phase II Trail of Bryostatin-1 and Paclitaxel in Patients With Advanced Esophageal Cancer Completed NCT00005599 Phase 2 bryostatin 1;paclitaxel
21 Phase II Trial of Preoperative Combined Modality Therapy for Localized Esophageal Carcinoma: Cisplatin-Paclitaxel Followed by Radiation Therapy With Concurrent Cisplatin and Paclitaxel Completed NCT00003087 Phase 2 cisplatin;paclitaxel
22 A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach Completed NCT00985192 Phase 2 everolimus
23 A Phase II Trial of Preoperative Radiation and Chemotherapy (Paclitaxel, Carboplatin, and Continuous Infusion 5-FU) for Locally Advanced Esophageal Cancer Completed NCT00022139 Phase 2 carboplatin;fluorouracil;paclitaxel
24 Phase II Evaluation Of Paclitaxel, Cisplatin And 5-Fluorouracil Given In Combination With Radiation Therapy Prior To Surgery In Patients With Resectable Esophageal Cancer Completed NCT00021320 Phase 2 cisplatin;fluorouracil;paclitaxel
25 A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
26 An Open-label, Multicenter Phase II Trial of Sunitinib for Patients With Chemo-refractory Metastatic Gastric Cancer Completed NCT00411151 Phase 2 Sunitinib-Malate
27 Non-Operative Therapy Of Local-Regional Carcinoma Of The Esophagus: A Randomizd Phase II Study Of Two Paclitaxel-Based Chemoradiotherapy Regimens Completed NCT00009880 Phase 2 cisplatin;fluorouracil;paclitaxel
28 A Phase II Study Of Hepatic Arterial Infusion Of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) For Unresectable Primary And Metastatic Cancers Of The Liver Completed NCT00096083 Phase 2 isolated perfusion;melphalan
29 Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer Completed NCT00381706 Phase 2 ECF;IC;FOLFOX
30 Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia Completed NCT00938470 Phase 2 capecitabine;docetaxel;fluorouracil;oxaliplatin
31 A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia Completed NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
32 A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1(Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer Completed NCT01498289 Phase 2 FOLFOX regimen;docetaxel;fluorouracil;irinotecan hydrochloride;leucovorin calcium;oxaliplatin
33 Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus Completed NCT00033657 Phase 2 cisplatin;irinotecan hydrochloride;paclitaxel
34 Paclitaxel Combined With 5-FU and Cisplatin Concomitant With Radiotherapy in the Management of Locally Advanced or Metastatic Esophageal Cancer (Adenocarcinoma and Squamous Histologies) - A Phase I/Modified Phase II Trial Completed NCT00002984 Phase 1, Phase 2 cisplatin;fluorouracil;paclitaxel
35 INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL Recruiting NCT02205047 Phase 2 Cisplatin;5-fluorouracil or Capecitabine;Trastuzumab;Pertuzumab
36 Phase 1/2 Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer Recruiting NCT02735239 Phase 1, Phase 2 Durvalumab;Tremelimumab;Oxaliplatin;Capecitabine;Paclitaxel;Carboplatin;5-fluorouracil (5-FU);Leucovorin;docetaxel
37 Study Title: Peri-operative Immuno-Chemotherapy in Operable Oesophageal and Gastric Cancer (ICONIC Trial) Recruiting NCT03399071 Phase 2 FLOT-A
38 A Phase II Trial Evaluating the Effectiveness of Itraconazole in Improving Pathologic Complete Response Rates in Patients With Esophageal Cancer Through Inhibition of the Hedgehog and AKT Signaling Pathways Recruiting NCT04018872 Phase 2 Itraconazole
39 Multi-Modality Treatment of Resectable Oesophageal Adenocarcinoma Using Peri-operative Chemotherapy With Additional Pre-operative Combined Radiotherapy and Cetuximab Terminated NCT00827671 Phase 2 cetuximab
40 A Trial Of Vaccination With The Carcinoembryonic Antigen (CEA) Peptide Cap 1-6D With Montanide ISA 51 Adjuvant Or Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) In HLA-A2+ Patients With CEA Producing Adenocarcinomas Of Gastrointestinal (GI) Tract Origin Terminated NCT00012246 Phase 2
41 PFL-Alpha Chemotherapy Followed by Surgery or FHX for Early Stage Esophageal Cancer - A Pilot Project Terminated NCT00004897 Phase 2 cisplatin;fluorouracil;hydroxyurea;leucovorin calcium
42 Effect of Zinc on Barrett's Metaplasia Unknown status NCT01984580 Phase 1 zinc gluconate
43 A Pilot Study of Tamoxifen in Oesophageal Cancer Unknown status NCT02513849 Phase 1 Tamoxifen
44 A Pilot Study To Determine The Maximum Range of Light Doses At Two HPPH Doses With Acceptable Normal Tissue Toxicity For PDT Treatment Of High Grade Dysplasia,CIS or Early Adenocarcinoma In Barrett's Esophagus Completed NCT01238042 Phase 1 HPPH
45 Phase I Trial of Combined Modality Irinotecan, Cisplatin, and Concurrent Radiation Therapy for Patients With Locally Advanced Esophageal Cancer Completed NCT00005638 Phase 1 cisplatin;irinotecan hydrochloride
46 A Phase I Study of Oxaliplatin in Combination With Continuous Infusion 5-Fluorouracil and Radiation in Esophageal Cancer Completed NCT00004257 Phase 1 fluorouracil;oxaliplatin
47 A PHASE I TRIAL OF COMBINED MODALITY THERAPY FOR LOCALIZED ESOPHAGEAL CANCER: CISPLATIN-PACLITAXEL FOLLOWED BY RADIATION THERAPY WITH CONCURRENT CISPLATIN AND ESCALATING DOSES OF PACLITAXEL Completed NCT00002711 Phase 1 chemotherapy;cisplatin;paclitaxel
48 Phase I Study of Vorinostat [Suberoylanilide Hydroxamic Acid (VORINOSTAT)] With Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (FOLFIRI) for Advanced Upper Gastrointestinal Cancers Completed NCT00537121 Phase 1 fluorouracil;irinotecan hydrochloride;leucovorin calcium;vorinostat
49 Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies Completed NCT00073944 Phase 1 forodesine hydrochloride
50 A Phase I, Multi-Dose Study of RAV12 (ANTI-RAAG12 MAB) in Patients With Metastatic or Recurrent Adenocarcinoma Completed NCT00101972 Phase 1

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Sources

Genetic Tests for Esophagus Adenocarcinoma

About this section
Sources

Anatomical Context for Esophagus Adenocarcinoma

About this section

MalaCards organs/tissues related to Esophagus Adenocarcinoma:

40
Breast, Lung, Skin, Bone, Colon, Liver, Tongue
Sources

Publications for Esophagus Adenocarcinoma

About this section

Articles related to Esophagus Adenocarcinoma:

(show top 50) (show all 96)
# Title Authors PMID Year
1
MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. 46
20301167 2010
2
Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus. 61
31605326 2020
3
Shared Genetic Etiology of Obesity-Related Traits and Barrett's Esophagus/Adenocarcinoma: Insights from Genome-Wide Association Studies. 61
31748258 2020
4
Size and Importance of Socioeconomic Status-Based Disparities in Use of Surgery in Nonadvanced Stage Gastrointestinal Cancers. 61
31605347 2020
5
Elective nodal irradiation versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. 61
31619265 2019
6
Prognostic Value of Tumor Regression Grade Based on Ryan Score in Squamous Cell Carcinoma and Adenocarcinoma of Esophagus. 61
31664618 2019
7
A multicenter phase III study comparing Simultaneous Integrated Boost (SIB) radiotherapy concurrent and consolidated with S-1 versus SIB alone in elderly patients with esophageal and esophagogastric cancer - the 3JECROG P-01 study protocol. 61
31036088 2019
8
Allergies and the Subsequent Risk of Cancer among Elderly Adults in the United States. 61
30700443 2019
9
Desmoplasia and Detached Papillae in Early Esophageal Adenocarcinoma: A Histologic Study on Endoscopic Submucosal Dissection Specimens. 61
31019616 2019
10
A Randomized Placebo-Controlled N-of-1 Trial: The Effect of Proton Pump Inhibitor in the Management of Gastroesophageal Reflux Disease. 61
31929980 2019
11
A six-microRNA signature can better predict overall survival of patients with esophagus adenocarcinoma. 61
31380150 2019
12
Barrett's Esophagus in Patients with Gastroesophageal Reflux Disease. 61
29983427 2018
13
Obesity and Cancer: Evidence, Impact, and Future Directions. 61
29038151 2018
14
Histopathological Assessment for Esophageal Adenocarcinoma. 61
29600360 2018
15
The arachidonic acid metabolism protein-protein interaction network and its expression pattern in esophageal diseases. 61
29636881 2018
16
Preliminary evaluation for Bit1 as a potential biomarker for squamous cell carcinoma and adenocarcinoma of esophagus. 61
28488526 2017
17
The clinical significance of cysteine dioxygenase type 1 methylation in Barrett esophagus adenocarcinoma. 61
28184414 2017
18
C-Met as a potential novel prognostic marker in squamous cell carcinoma and adenocarcinoma of esophagus: evidence from a meta-analysis. 61
27636117 2017
19
Epigenetic regulation on the gene expression signature in esophagus adenocarcinoma. 61
28049580 2017
20
Racial Differences in Esophageal Squamous Cell Carcinoma: Incidence and Molecular Features. 61
28393072 2017
21
The different functions and clinical significances of caveolin-1 in human adenocarcinoma and squamous cell carcinoma. 61
28243118 2017
22
Oral squamous cell cancer protein-protein interaction network interpretation in comparison to esophageal adenocarcinoma. 61
28744358 2017
23
[The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus]. 61
30615323 2016
24
Detection of human papillomavirus DNA in gastric carcinoma specimens in a high-risk region of Iran. 61
27588180 2016
25
Trajectory of body shape across the lifespan and cancer risk. 61
26704725 2016
26
Four Synchronous Primary Malignancies of the Breast, Lung, Colon and Esophagus. 61
26504043 2015
27
Simultaneous Esophageal Squamous Cell Carcinoma and Adenocarcinoma: A Case Report. 61
26609356 2015
28
Predictive Value of the Neutrophil/Lymphocyte Ratio in Peritoneal and/or Metastatic Disease at Staging Laparoscopy for Gastric and Esophageal Adenocarcinoma. 61
25952408 2015
29
First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. 61
25947566 2015
30
Analysis of AC3-33 gene expression in multiple organ cancer and adjacent normal tissue by RNA in situ hybridization. 61
26137149 2015
31
In vivo molecular imaging of HER2 expression in a rat model of Barrett's esophagus adenocarcinoma. 61
24708360 2015
32
Prolonged Impacted Denture in the Esophagus: A Case Report and Review of the Literature. 61
27162898 2015
33
Four cases of adenocarcinoma of esophagus with co-existing hydatid cyst of liver which caused delayed management of carcinoma esophagus. 61
24869991 2015
34
Unusual metastasis of esophageal cancer. 61
25518280 2014
35
Esophagus adenocarcinoma in a young patient with celiac disease; Is celiac disease a predisposing factor for esophagus adenocarcinoma as well as squamous cell carcinoma? 61
26185881 2014
36
Research on the typical miRNA and target genes in squamous cell carcinoma and adenocarcinoma of esophagus cancer with DNA microarray. 61
24519530 2014
37
OCT3 and SOX2 promote the transformation of Barrett's esophagus to adenocarcinoma by regulating the formation of tumor stem cells. 61
24481676 2014
38
Radiotherapy in the multimodality management of esophageal cancer. 61
25799618 2014
39
Esophagogastric metaplasia relates to nodal metastases in adenocarcinoma of esophagus and cardia. 61
23434259 2013
40
MUTYH association with esophageal adenocarcinoma in a Han Chinese population. 61
24377542 2013
41
Increase of epidermal growth factor receptor expression in progression of GERD, Barrett, and adenocarcinoma of esophagus. 61
22875307 2013
42
Aberrant expression of Wnt and Notch signal pathways in Barrett's esophagus. 61
22889748 2012
43
Association of methylenetetrahydrofolate reductase C677T-A1298C polymorphisms with risk for esophageal adenocarcinoma, Barrett's esophagus, and reflux esophagitis. 61
21951971 2012
44
Comparative evaluation of serum C-reactive protein (CRP) levels in the different histological subtypes of esophageal cancer (squamous cell carcinoma and adenocarcinoma of esophagus). 61
22467322 2012
45
Hedgehog signaling activation in the development of squamous cell carcinoma and adenocarcinoma of esophagus. 61
22509480 2012
46
Endoscopic imaging in Barrett's esophagus: current practice and future applications. 61
24714225 2012
47
Photodynamic therapy (PDT) using HPPH for the treatment of precancerous lesions associated with Barrett's esophagus. 61
22057498 2011
48
Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis. 61
21166737 2011
49
Does impaired gallbladder function contribute to the development of Barrett's esophagus and esophageal adenocarcinoma? 61
21484485 2011
50
Significance of platelet count in esophageal carcinomas. 61
21372352 2011
Sources

Variations for Esophagus Adenocarcinoma

About this section
Sources

Expression for Esophagus Adenocarcinoma

About this section
Search GEO for disease gene expression data for Esophagus Adenocarcinoma.
Sources

Pathways for Esophagus Adenocarcinoma

About this section

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Pathways in cancer 36
12.58 TP53 PTGS2 ERBB2 EGFR CDKN2A
2
Gastric cancer 36
Show member pathways
 12.47 TP53 ERBB2 EGFR CDX2 CDKN2A
3
Development Ligand-independent activation of ESR1 and ESR2 22
Show member pathways
 11.95 PTGS2 ERBB2 EGFR CDO1
4
Proteoglycans in cancer 36
11.87 TP53 MIR21 ERBB2 EGFR
5
MicroRNAs in cancer 36
11.81 TP53 PTGS2 MIR330 MIR215 MIR21 MIR145
6
Platinum drug resistance 36
11.47 TP53 ERBB2 CDKN2A
7
Central carbon metabolism in cancer 36
11.38 TP53 ERBB2 EGFR
8
Bladder cancer 36 1
11.12 TP53 ERBB2 EGFR CDKN2A
9
Photodynamic therapy-induced AP-1 survival signaling. 1
11.04 TP53 EGFR CDKN2A
Sources

GO Terms for Esophagus Adenocarcinoma

About this section

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 PTGS2 MIR21 ERBB2 EGFR CDX2
2 positive regulation of protein kinase B signaling GO:0051897 9.76 MIR21 MIR143 ERBB2 EGFR
3 negative regulation of G1/S transition of mitotic cell cycle GO:2000134 9.67 MIR21 MIR193A CDKN2A
4 negative regulation of angiogenesis GO:0016525 9.62 MIR21 MIR193A MIR145 MIR143
5 replicative senescence GO:0090399 9.56 TP53 CDKN2A
6 sodium ion export across plasma membrane GO:0036376 9.55 ATP4A ATP12A
7 gene silencing by miRNA GO:0035195 9.55 MIR21 MIR196A1 MIR193A MIR145 MIR143
8 cellular potassium ion homeostasis GO:0030007 9.54 ATP4A ATP12A
9 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.52 TP53 EGFR
10 angiotensin-activated signaling pathway GO:0038166 9.51 MIR145 MIR143
11 negative regulation of ERBB signaling pathway GO:1901185 9.48 ERBB2 EGFR
12 aorta smooth muscle tissue morphogenesis GO:0060414 9.43 MIR145 MIR143
13 negative regulation of smooth muscle cell proliferation GO:0048662 9.43 TP53 MIR145 MIR143
14 negative regulation of immature T cell proliferation in thymus GO:0033088 9.4 ERBB2 CDKN2A
15 regulation of phenotypic switching GO:1900239 9.37 MIR145 MIR143
16 regulation of ERK1 and ERK2 cascade GO:0070372 9.13 MIR145 ERBB2 EGFR
17 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 8.62 MIR145 MIR143

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.5 TP53 ERBB2 EGFR
2 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
3 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
4 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.02 MIR21 MIR196A1 MIR193A MIR145 MIR143
5 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A
Sources

Sources for Esophagus Adenocarcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....